Effects of treatment interruption on anatomical and functional status of eyes with neovascular age-related macular degeneration receiving anti-VEGF therapy

Abstract

AIM: To study anatomical and functional changes in eyes with neovascular age-related macular degeneration (AMD) receiving anti-VEGF therapy and experienced treatment interruption during COVID pandemic.

MATERIAL AND METHODS: This retrospective study included 58 eyes (49 patients, 34 males and 15 females with a mean age of 73.2 ± 9.4 years) with nAMD. Eyes in the first-year treatment group (18 eyes) received up to 7 intravitreal aflibercept injections, eyes in the second-year treatment group (21 eyes) were treated with pro re nata regimen. The treatment interruption period in the first and second-year treatment group was 5.5 ± 0.7 and 5.5 ± 1.0 months, respectively.

RESULTS: Over the treatment interruption period, the first-year treatment group showed no statistically significant differences in best-corrected visual acuity (BCVA) and central retinal thickness (CRT), p = 0.25 and p = 0.09, respectively. At the same time, the second-year treatment group showed a statistically significant decrease in BCVA (p = 0.0004) and an increase in CRT (p = 0.002). Baseline BCVA was positively associated with BCVA at the end of treatment interruption (r = 0.82; p < 0.0001). Presence of sub- and intraretinal fluid (p = 0.015 and p = 0.007, respectively), low BCVA (p < 0.0001), high CRT (p = 0.019), alteration of the ellipsoid zone (p < 0.001) were negatively associated with BCVA at the end of treatment interruption. Age (p = 0.8), gender (p = 0.41), and the number of intravitreal injections (p = 0.5) showed no association with changes in BCVA.

CONCLUSIONS: NAMD patients of the second year of anti-VEGF therapy appear to have a higher risk of functional loss during treatment interruption. Higher CRT and lower BCVA, as well as sub- and intraretinal fluid before treatment interruption, are associated with poorer functional status at the end of the interruption period.

Keywords

neovascular age-related macular degeneration / anti-VEGF therapy / aflibercept / optical coherence tomography / COVID-19

References

[1] Regillo CD, Busbee BG, Ho AC, et al. Baseline predictors of 12-Month treatment response to ranibizumab in patients with wet age-related macular degeneration. Am J Ophthalmol. 2015;160(5):1014–1023. DOI: 10.1016/j.ajo.2015.07.034

[2] Regillo C.D., Busbee B.G., Ho A.C., et al. Baseline predictors of 12-Month treatment response to ranibizumab in patients with wet age-related macular degeneration // Am J Ophthalmol. 2015. Vol. 160, No. 5. P. 1014–1023. DOI: 10.1016/j.ajo.2015.07.034

[3] Hayashi H, Yamashiro K, Tsujikawa A, et al. Association between foveal photoreceptor integrity and visual outcome in neovascular age-related macular degeneration. Am J Ophthalmol. 2009;148(1):83–89. DOI: 10.1016/j.ajo.2009.01.017

[4] Hayashi H., Yamashiro K., Tsujikawa A., et al. Association between foveal photoreceptor integrity and visual outcome in neovascular age-related macular degeneration // Am J Ophthalmol. 2009. Vol. 148, No. 1. P. 83–89. DOI: 10.1016/j.ajo.2009.01.017

[5] Kharakozov AS, Kulikov AN, Maltsev DS. Predictors of functional outcome of antiangiogenic therapy in neovascular age-related macular degeneration. Ophthalmology Journal. 2020;13(4):7-13. (In Russ.)] DOI: 10.17816/OV46198

[6] Харакозов А.С., Куликов А.Н., Мальцев Д.С. Предикторы функционального результата антиангиогенной терапии влажной формы возрастной макулярной дегенерации // Офтальмологические ведомости. 2020. Т. 13, № 4. С. 7–13. DOI: 10.17816/OV46198

[7] Ou WC, Brown DM, Payne JF, et al. Relationship between visual acuity and retinal thickness during anti-vascular endothelial growth factor therapy for retinal diseases. Am J Ophthalmol. 2017;180:8–17. DOI: 10.1016/j.ajo.2017.05.014

[8] Ou W.C., Brown D.M., Payne J.F., et al. Relationship between visual acuity and retinal thickness during anti-vascular endothelial growth factor therapy for retinal diseases // Am J Ophthalmol. 2017. Vol. 180. P. 8–17. DOI: 10.1016/j.ajo.2017.05.014

[9] Boiko EV, Maltsev DS. Quantitative optical coherence tomography analysis of retinal degenerative changes in diabetic macular edema and neovascular age-related macular degeneration. Retina. 2018;38(7):1324–1330. DOI: 10.1097/IAE.0000000000001696

[10] Boiko EV, Maltsev DS Quantitative optical coherence tomography analysis of retinal degenerative changes in diabetic macular edema and neovascular age-related macular degeneration. Retina. 2018. Vol. 38, No. 7. P. 1324–1330. DOI: 10.1097/IAE.0000000000001696

[11] Kulikov AN, Sosnovskii SV, Berezin RD, et al. Vitreoretinal interface abnormalities in diabetic macular edema and effectiveness of anti-VEGF therapy: an optical coherence tomography study. Clin Ophthalmol. 2017;11:1995–2002. DOI: 10.2147/OPTH.S146019

[12] Kulikov A.N., Sosnovskii S.V., Berezin R.D., et al. Vitreoretinal interface abnormalities in diabetic macular edema and effectiveness of anti-VEGF therapy: an optical coherence tomography study // Clin Ophthalmol. 2017. Vol. 11. P. 1995–2002. DOI: 10.2147/OPTH. S146019

[13] American Academy of Ophthalmology. Alert: Important coronavirus updates for ophthalmologists. March 23, 2020. Available at: https://www.aao.org/headline/alert-important-coronavirus-context. Accessed: 25.03.2021.

[14] American Academy of Ophthalmology. Alert: Important coronavirus updates for ophthalmologists. March 23, 2020. Режим доступа: https://www.aao.org/headline/alert-important-coronavirus-context Дата обращения: 25.03.2021.

[15] Antaki F, Dirani A. Treating neovascular age-related macular degeneration in the era of COVID-19. Graefes Arch Clin Exp Ophthalmol. 2020;258(7):1567–1569. DOI: 10.1007/s00417-020-04693-w

[16] Antaki F., Dirani A. Treating neovascular age-related macular degeneration in the era of COVID-19 // Graefes Arch Clin Exp Ophthalmol. 2020. Vol. 258, No. 7. P. 1567–1569. DOI: 10.1007/s00417-020-04693-w

[17] Wong DHT, Mak ST, Yip NKF, et al. Protective shields for ophthalmic equipment to minimise droplet transmission of COVID-19. Graefes Arch Clin Exp Ophthalmol. 2020;258(7):1571–1573. DOI: 10.1007/s00417-020-04683-y

[18] Wong D.H.T., Mak S.T., Yip N.K.F., et al. Protective shields for ophthalmic equipment to minimise droplet transmission of COVID-19 // Graefes Arch Clin Exp Ophthalmol. 2020. Vol. 258, No. 7. P. 1571–1573. DOI: 10.1007/s00417-020-04683-y

[19] Sacconi R, Borrelli E, Vella G, et al. TriPla regimen: A new treatment approach for patients with neovascular age-related macular degeneration in the COVID-19 “era”. Eur J Ophthalmol. 2020;7:1120672120963448. DOI: 10.1177/1120672120963448

[20] Sacconi R., Borrelli E., Vella G., et al. TriPla regimen: A new treatment approach for patients with neovascular age-related macular degeneration in the COVID-19 “era” // Eur J Ophthalmol. 2020. Vol. 7. P. 1120672120963448. DOI: 10.1177/1120672120963448

[21] The Royal College of Ophthalmologists (2020) Medical retinal management plans during COVID-19. Available at: https://www.rcophth.ac.uk/wp-content/uploads/2020/03/Medical-Retinal-Management-Planduring-COVID-19-UPDATED-300320-1-2.pdf. Accessed 25.03.2021.

[22] The Royal College of Ophthalmologists (2020) Medical retinal management plans during COVID-19. Режим доступа: https://www.rcophth.ac.uk/wp-content/uploads/2020/03/Medical-Retinal-Management-Planduring-COVID-19-UPDATED-300320-1-2.pdf.

RIGHTS & PERMISSIONS

Kharakozov A.S., Kulikov A.N., Maltsev D.S.